SPOTLIGHT: Better times ahead for BMS?
With its two-year federal probationary period coming to an end, the Wall Street Journal reports that the dark clouds may be lifting from Bristol-Myers Squibb. An earnings report from BMS is due on Thursday, and analysts are expecting some word on the company's search for a new CEO. Investors are also looking for some insight into the damage done by the temporary sale of a generic competitor to Plavix. Report (WSJ sub. req.)
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets


